Boehringer Ingelheim names Yew Looi Liew president of U.S. human pharma

Boehringer Ingelheim has named Yew Looi Liew as president of U.S. human pharma.

Liew, formerly the corporate senior vice president and head of human pharma for BI’s Emerging Markets region, succeeds Jean-Michel Boers. In his new role, Liew is responsible for ensuring the successful development of the current human pharma portfolio and preparing the organization for future launches.

“I am energized by the passion YL brings to Boehringer Ingelheim every day to help transform the lives of patients,” said Jean-Michel Boers, president and CEO, and U.S.country managing director at Boehringer Ingelheim USA. “Having witnessed the rapid growth of the Emerging Markets region under his leadership, I look forward to the positive impact he will have on the continued successful development of our current cardiovascular & metabolic, respiratory and specialty care franchises, and the future growth of our pipeline.”

Liew said, “I have been quite impressed with the agility, perseverance and success of the Human Pharma US team, especially during this unprecedented time. I want to build upon these successes through adding value and always operating on the leading edge of innovation to help make life-enhancing healthcare improvements. Together, we will be an ambitious team that focuses on our impact for patients at the center of all we do.”

In his prior role, Liew spent the past seven years managing the company’s emerging markets efforts in Greater China, South East Asia, South Asia, South Korea, the Middle East, Africa, Mexico, Central America and South America, which grew to nearly seven thousand employees during his tenure.

Liew holds a bachelor’s degree in pharmacy from the University of Science, Malaysia and a Master of Business Administration from the University of Hull in the UK. He also completed the General Management Development Program from CEDEP, INSEAD in Fontainebleau, France.

Prior to joining BI in 2013, Liew held senior leadership roles with a number of pharmaceutical companies, including Janssen and Bristol-Myers Squibb. He has held roles in sales, marketing, regulatory, clinical, manufacturing and general management in countries all over the world, including China, the Philippines, Taiwan, South Korea, Singapore, and his home country of Malaysia.